<DOC>
	<DOCNO>NCT02623738</DOCNO>
	<brief_summary>The purpose study determine optimal concentration DE-117 ophthalmic solution compare placebo ophthalmic solution determine intraocular pressure reduction 4 week treatment DE-117 ophthalmic solution non-inferior latanoprost ophthalmic solution 0.005 % .</brief_summary>
	<brief_title>A Study Assessing Efficacy Safety DE-117 Ophthalmic Solution Subjects With Primary Open Angle Glaucoma Ocular Hypertension -AYAME Study-</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Primary open angle glaucoma ocular hypertension Patients risk progression visual field loss Patients severe visual field defect Patients diseases preclude participation study safety reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>